System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

George G Zhanel, PhD is an expert in Infectiology at University of Manitoba (Canada). George G Zhanel has authored 514 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 1 of them ongoing. SLR score: 1,694 (community average: 125). How the SLR is computed.

LeadR Profile

George G Zhanel, PhD University of Manitoba Canada
1 694 ScienceLeadR Reputation 1694

Unlock

Register Login
Network Map

Infectiology

Subspecialties: Pharmacy - Public Health - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Dr. George Zhanel is a microbiologist and pharmacologist who received his Ph.D. in the Department of Medical Microbiology/Infectious Diseases at the Faculty of Medicine, University of Manitoba and a Doctor of Clinical Pharmacy at the University of Minnesota (magna cum laude).

He is presently Professor and Associate Head, Department of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine and Research Director of the Canadian Antimicrobial Resistance Alliance (CARA). Dr Zhanel is the founding/ Chief Editor of the CARA website (www.can-r.com).


Dr. Zhanel has published over 1350 papers, scientific abstracts/posters and book chapters in the area of treatment and prevention of infectious diseases. He has presented over 1300 lectures as an invited speaker at international, national, and local meetings speaking on the topics of antimicrobial resistant infections as well as treatment and prevention of infectious diseases in Canada, United States, Central and South America, Western and Eastern Europe including Russia, Australia, Southern and Northern Africa, the Middle East and Asia. He has been extensively involved in treatment guidelines for a variety of infections in Canada, the US and internationally.


Dr. Zhanel has received or been nominated for > 118 teaching awards including the Canadian Association for Medical Education (CAME) merit teaching award in 2020. Dr. Zhanel is a member of the Who’s Who in Medical Sciences Education (WWMSE). In 2022, he was elected as a fellow of the Canadian Academy of Health Sciences (CAHS) in recognition of sustained excellence in research and teaching within the health sciences. Fellowship in the Academy is considered one of the highest honours for individuals in the Canadian health sciences community. Also In 2022, Dr. Zhanel received the Dr. Fred Aoki Career Achievement Award in recognition of a career of dedication and excellence in multiple domains of medical microbiology and infectious diseases including, research, education, clinical practice, service and administration.


Organizations

Career arc: 1988 - 2026
Source: PubMed

University of Manitoba

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 514

Citations

Citations: 23 181 1st author: 136 Last author: 182 Unique author: 7

Main journals

J Antimicrob Chemother 92
Antimicrob Agents Chemother 81
Diagn Microbiol Infect Dis 40
Can J Infect Dis Med Microbiol 27
Int J Antimicrob Agents 23

Best Journals

N Engl J Med 2
JAMA 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Investigation of colistin-resistant non-human Acinetobacter seifertii isolates.
PMID 42752203 — milk, colistin, health resorts, pharmaceutical preparations, lipidomics, membranes, infections, acinetobacter		Microbiol Spectr20260
Genomic prediction of antimicrobial resistance in priority healthcare pathogens using Staramr.
PMID 42836344 — research design, genes, genome, vancomycin, escherichia coli, bacteria, methicillin, infections		Microbiol Spectr20260
Clinical use of dalbavancin in Canada: the clear study final results.
PMID 42788820 — registries, bacteremia, skin, osteomyelitis, methicillin-resistant staphylococcus aureus, endocarditis, therapeutics, infections		Expert Rev Anti Infect Ther20260
Invasive pneumococcal disease surveillance in Canada, 2023.
PMID 41924395 — pneumococcal infections, laboratories, vaccines, prevalence, streptococcus pneumoniae		Can Commun Dis Rep20261
'Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018-2021-right-to-reply'.
PMID 41913952 — epidemiology, pneumococcal infections, streptococcus, vaccines, drug therapy, pneumococcal vaccines, streptococcus pneumoniae		J Antimicrob Chemother20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 4 2
N/A 1

By status:

Terminated 2
Not yet recruiting 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 2
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Bearberry in the Treatment of Cystitis
NCT05055544 — urinary bladder, powders, urinary tract, cystitis, tablets, fosfomycin, signs and symptoms, urination, urinary tract infections, plants, medicinal, therapeutics, bacteria, infections, women		N/ANot yet recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS